Alzheimer's

19 May 2018, Cavendish Conference Centre, London

Booking is now closed.

This IHCAN Conference is now over, and the rest of the 2018 series is close to selling out, so we recommend you book your place as soon as possible to avoid disappointment.

Expert speaker

Course gluten-free lunch

Exhibitors

CPD hours/points

9.30 – 10.00
Registration

Enjoy teas, herbal teas, coffee, and seasonal cut fruit during registration.

10.00- 11.30
Dr Dale Bredesen

First Survivors of Alzheimer’s: What Have We Learned?

Professor of Neurology Easton Laboratories for Neurodegenerative Disease Research David Geffen School of Medicine at UCLA, Los Angeles, CA Founding President and CEO, Professor Emeritus, Buck Institute for Research on Aging, Novato, CA.

Dr. Bredesen received his undergraduate degree from Caltech and his medical degree from Duke.  He served as Resident and Chief Resident in Neurology at UCSF, then was postdoctoral fellow in the laboratory of Nobel laureate Prof. Stanley Prusiner.  He was a faculty member at UCLA from 1989-1994, then was recruited by the Burnham Institute to direct the Program on Aging.  In 1998 he became the Founding President and CEO of the Buck Institute for Research on Aging, and Adjunct Professor at UCSF; then in 2013 he returned to UCLA as the Director of the Easton Center for Alzheimer’s Disease Research.

The Bredesen Laboratory studies basic mechanisms underlying the neurodegenerative process, and the translation of this knowledge into effective therapeutics for Alzheimer’s disease and other neurodegenerative conditions, leading to the publication of over 220 research papers. He established the ADDN (Alzheimer’s Drug Development Network) with Dr. Varghese John in 2008, leading to the identification of new classes of therapeutics for Alzheimer’s disease.  His group has developed a new approach to the treatment of Alzheimer’s disease, and this approach has led to the discovery of subtypes of Alzheimer’s disease, followed by the first description of reversal of symptoms in patients with MCI and early Alzheimer’s disease, with the ReCODE (reversal of cognitive decline) protocol, published in 2014 and 2016. His book, The End of Alzheimer’s, is a New York Times Bestseller.

11.30 – 12.30
Refreshments

Enjoy teas, herbal teas, coffee, and seasonal cut fruit during this time.

12.30 – 13.30
Dr Dale Bredesen

First Survivors of Alzheimer’s: What Have We Learned?

Professor of Neurology Easton Laboratories for Neurodegenerative Disease Research
David Geffen School of Medicine at UCLA, Los Angeles, CA
Founding President and CEO, Professor Emeritus, Buck Institute for Research on Aging, Novato, CA

Dr. Bredesen received his undergraduate degree from Caltech and his medical degree from Duke.  He served as Resident and Chief Resident in Neurology at UCSF, then was postdoctoral fellow in the laboratory of Nobel laureate Prof. Stanley Prusiner.  He was a faculty member at UCLA from 1989-1994, then was recruited by the Burnham Institute to direct the Program on Aging.  In 1998 he became the Founding President and CEO of the Buck Institute for Research on Aging, and Adjunct Professor at UCSF; then in 2013 he returned to UCLA as the Director of the Easton Center for Alzheimer’s Disease Research.

The Bredesen Laboratory studies basic mechanisms underlying the neurodegenerative process, and the translation of this knowledge into effective therapeutics for Alzheimer’s disease and other neurodegenerative conditions, leading to the publication of over 220 research papers. He established the ADDN (Alzheimer’s Drug Development Network) with Dr. Varghese John in 2008, leading to the identification of new classes of therapeutics for Alzheimer’s disease.  His group has developed a new approach to the treatment of Alzheimer’s disease, and this approach has led to the discovery of subtypes of Alzheimer’s disease, followed by the first description of reversal of symptoms in patients with MCI and early Alzheimer’s disease, with the ReCODE (reversal of cognitive decline) protocol, published in 2014 and 2016.  His book, The End of Alzheimer’s, is a New York Times Bestseller.

13.30 – 14.30
Lunch

Enjoy a three course gluten-free buffet lunch, with time to network with peers and exhibitors.

14.30 – 16.30
Dr Dale Bredesen

First Survivors of Alzheimer’s: What Have We Learned?

Professor of Neurology Easton Laboratories for Neurodegenerative Disease Research David Geffen School of Medicine at UCLA, Los Angeles, CA Founding President and CEO, Professor Emeritus, Buck Institute for Research on Aging, Novato, CA.

Dr. Bredesen received his undergraduate degree from Caltech and his medical degree from Duke. He served as Resident and Chief Resident in Neurology at UCSF, then was postdoctoral fellow in the laboratory of Nobel laureate Prof. Stanley Prusiner. He was a faculty member at UCLA from 1989-1994, then was recruited by the Burnham Institute to direct the Program on Aging. In 1998 he became the Founding President and CEO of the Buck Institute for Research on Aging, and Adjunct Professor at UCSF; then in 2013 he returned to UCLA as the Director of the Easton Center for Alzheimer’s Disease Research.

The Bredesen Laboratory studies basic mechanisms underlying the neurodegenerative process, and the translation of this knowledge into effective therapeutics for Alzheimer’s disease and other neurodegenerative conditions, leading to the publication of over 220 research papers. He established the ADDN (Alzheimer’s Drug Development Network) with Dr. Varghese John in 2008, leading to the identification of new classes of therapeutics for Alzheimer’s disease. His group has developed a new approach to the treatment of Alzheimer’s disease, and this approach has led to the discovery of subtypes of Alzheimer’s disease, followed by the first description of reversal of symptoms in patients with MCI and early Alzheimer’s disease, with the ReCODE (reversal of cognitive decline) protocol, published in 2014 and 2016. His book, The End of Alzheimer’s, is a New York Times Bestseller.

Booking is now closed.

This IHCAN Conference is now over, and the rest of the 2018 series is close to selling out, so we recommend you book your place as soon as possible to avoid disappointment.

Book any of the remaining events for only £95 (inc. VAT), with a multiple booking discount available for booking more than one event and additional discounts available for students and associations.

Book your place before it's too late...

Day(s)

:

Hour(s)

:

Minute(s)

:

Second(s)

Proudly supported by

Book your place